BOSTON, March 25, 2025 /PRNewswire/ -- Linus Health, recognized for pioneering brain health solutions, is set to present pivotal findings from two clinical studies at the upcoming AD/PD™ 2025 conference, an influential gathering focusing on Alzheimer's and Parkinson's diseases. This significant event will take place from April 1-5 in Vienna, Austria, marking its 40th year of bringing together global experts in neurodegenerative disorders.
Last year, the AD/PD conference drew over 4,700 healthcare and life sciences professionals from more than 70 countries, showcasing the urgency and relevance of research in this field. At this year's conference, Linus Health's poster presentations will detail the efficacy of their digital health solutions, particularly the Linus Health DCTclock™, and a new Digital Assessment of Cognition (DAC).
Dr. Ali Jannati, Linus Health's director of Cognitive Science, will present findings demonstrating that the DCTclock™ effectively detects cognitive impairment in patients with Parkinson's disease. Moreover, it quantifies drawing tremors, a crucial metric for assessing motor function. The study highlights that the DCTclock's Oscillatory Motion (OM) metric closely aligns with clinician ratings, establishing it as a sensitive endpoint relevant to cognitive and motor impairment assessments.
In a parallel effort, the validation study for the Digital Assessment of Cognition has shown impressive results, achieving high accuracy in classifying cognitive status similar to traditional, lengthy evaluations. Dr. Jannati emphasized, "We are excited to present two of the recent validations of our evidence-based digital cognitive health platform at a leading global conference on the most innovative science and therapy surrounding Alzheimer's and Parkinson's disease." These developments suggest a promising future for scalable, effective cognitive evaluations and enhancements in patient care.
Meanwhile, Annovis Bio, a late-stage clinical drug platform company focused on transformative therapies, announced its participation in AD/PD™ 2025. CEO Maria Maccecchini expressed enthusiasm about their advancements, stating, "At this meeting, we will present comprehensive data from our latest Phase 3 PD and Phase 2/3 AD studies." Annovis will present findings on their drug, buntanetap, which shows cognitive and motor function improvement in early Parkinson's patients. Another presentation scheduled for April 2 will examine advantages for APOE4 carriers in Alzheimer's patients.
The AD/PD conference aims to accelerate the sharing of breakthroughs in clinical trial methodologies and therapeutic developments, equipping researchers and healthcare professionals with innovative tools. On April 4, Dr. Maccecchini will join a forum discussion focusing on novel biomarkers and therapies associated with α-synuclein, laying groundwork for significant advancements in understanding diseases like Parkinson's Disease, Lewy Body Dementia (LBD), and Multiple System Atrophy (MSA).
Both Linus Health and Annovis Bio underscore the critical intersection of research and real-world applications. Linus Health, noted for its acquisition of Aural Analytics in 2024, emphasizes expanding its capabilities in life sciences to boost clinical trial efficiency. As more pharmaceutical organizations partner with them, these collaborations aim to foster robust outcomes in brain health therapies, tackling conditions such as Alzheimer's, Parkinson's, and ALS.
Linus Health's strategies, including their comprehensive library of peer-reviewed studies and operational efficiencies, further enhance the value of their offerings in neurodegenerative research. These advancements not only pave the way for strengthening outcome measures in clinical trials but facilitate monitoring long-term treatment efficacy in real-world settings.
In his remarks, Linus Health's CEO, Dr. David Bates, emphasized the impact of their research on clinical trials: "Linus Health is working with more pharma and life sciences companies than ever before because we help solve their most pressing challenge: increasing clinical trial efficiency and success while maintaining scientific rigor." His insights reflect a broader industry momentum pushing for innovations that elevate patient outcomes.
As AD/PD™ 2025 approaches, both Linus Health and Annovis Bio stand ready to showcase their research achievements and engage with other leaders and professionals in neurodegenerative disease treatment. Their presentations are vital, promising insights that may influence future therapeutic directions and clinical frameworks.
The AD/PD conference not only highlights the latest innovations but also reaffirms an ongoing commitment among scientists, healthcare providers, and biopharma companies to advance solutions for Alzheimer's and Parkinson's diseases, reshaping approaches to neurodegenerative disorder management worldwide.
